Baxter International Inc (BAX) Holdings Boosted by Shelton Capital Management
Shelton Capital Management raised its holdings in Baxter International Inc (NYSE:BAX) by 52.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 103,306 shares of the medical instruments supplier’s stock after acquiring an additional 35,400 shares during the quarter. Shelton Capital Management’s holdings in Baxter International were worth $6,678,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Goelzer Investment Management Inc. lifted its stake in Baxter International by 13.6% in the fourth quarter. Goelzer Investment Management Inc. now owns 7,677 shares of the medical instruments supplier’s stock valued at $496,000 after buying an additional 922 shares during the period. Teacher Retirement System of Texas lifted its stake in Baxter International by 59.7% in the fourth quarter. Teacher Retirement System of Texas now owns 750,850 shares of the medical instruments supplier’s stock valued at $48,535,000 after buying an additional 280,597 shares during the period. ING Groep NV lifted its stake in Baxter International by 69.0% in the fourth quarter. ING Groep NV now owns 64,373 shares of the medical instruments supplier’s stock valued at $4,161,000 after buying an additional 26,278 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in Baxter International by 1.5% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 78,082 shares of the medical instruments supplier’s stock valued at $5,329,000 after buying an additional 1,163 shares during the period. Finally, Crossmark Global Holdings Inc. lifted its stake in Baxter International by 47.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 79,076 shares of the medical instruments supplier’s stock valued at $5,111,000 after buying an additional 25,522 shares during the period. 83.54% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have issued reports on BAX. Royal Bank of Canada reissued a “hold” rating and issued a $66.00 price target on shares of Baxter International in a research note on Wednesday, November 22nd. Citigroup upped their target price on Baxter International from $66.00 to $70.00 and gave the stock a “neutral” rating in a research report on Tuesday. Morgan Stanley upped their target price on Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 26th. BMO Capital Markets upped their target price on Baxter International from $74.00 to $77.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Seven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $70.36.
Baxter International Inc (NYSE BAX) opened at $62.56 on Friday. The company has a current ratio of 2.80, a quick ratio of 2.22 and a debt-to-equity ratio of 0.37. Baxter International Inc has a 12-month low of $48.40 and a 12-month high of $72.58. The firm has a market capitalization of $34,080.00, a P/E ratio of 48.12, a PEG ratio of 1.86 and a beta of 0.78.
Baxter International (NYSE:BAX) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.77 billion. Baxter International had a return on equity of 15.12% and a net margin of 6.79%. Baxter International’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.57 earnings per share. research analysts predict that Baxter International Inc will post 2.78 EPS for the current fiscal year.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.